Market Overview

ZIOPHARM Announces Positive Phase 1/2 Interim Results for Ad-RTS-IL-12 in Patients With Advanced Melanoma


ZIOPHARM Oncology (Nasdaq: ZIOP) today announced positive interim results from its ongoing Phase 1/2 study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate that is being evaluated with the oral activator, veledimex, in patients with advanced melanoma. The results from this multicenter study were presented at Melanoma Bridge 2013 Conference at the session "Best Abstracts on News in Immunotherapy", an international conference co-sponsored by Istituto Nazionale Tumori Fondazione, Sidra Medical and Research Center, and the Society for ImmunoTherapy of Cancer that is being held in Naples, Italy.

See full press release

Posted-In: News Guidance Management


Related Articles (ZIOP + XON)

View Comments and Join the Discussion!